Biotech initiatives pick up as more regions race to become hubs

New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.

By Alexandra Pecci • Aug. 13, 2026

Formation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’

Dr. Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.

By Alexandra Pecci • Aug. 12, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Drugs that missed the mark in pharma’s last earnings round

Why treatments from Alnylam, Merck, AbbVie and Roche stumbled in the last quarter.

By Kelly Bilodeau • Aug. 11, 2026

Trump signs order seeking to upend childhood vaccine schedule

The executive order — which wasn’t accompanied by any new scientific evidence — aims to split the MMR vaccine into three separate shots and revives the administration’s attempt to slim down the immunization schedule.

By Delilah Alvarado • Aug. 11, 2026

Did Novo’s phase 3 flop kill the inflammation hypothesis in heart disease?

While a disappointing late-stage readout sent biotech stocks tumbling, all hope may not be lost for the emerging approach to treating cardiovascular events.

By Kelly Bilodeau • Aug. 10, 2026

Large pharmas skirt tariffs; BMS’ dealmaking drought

Big Pharmas won't get hit new levies on branded drugs; and aside from the megamerger rumors, BMS has had a relatively quiet year for M&A.

By PharmaVoice Staff • Aug. 7, 2026

Why Big Pharma is chasing the industry’s most-powerful supercomputer

BMS is the latest major drugmaker to tap Nvidia for more computing power, betting that larger models and AI agents can speed drug discovery.

By Alexandra Pecci • Aug. 7, 2026

Erica Schwartz confirmed as next CDC director

Schwartz will step into an agency that has been without a permanent leader for almost a year amid RFK Jr.’s tumultuous tenure as HHS chief. 

By Kristin Jensen • Aug. 6, 2026

What the AstraZeneca-BMS rumors reveal about pharma megamergers

Reports of talks were quickly disputed, but the prospect exposed the appeal — and antitrust risks — of combining two pharma giants.

By Kelly Bilodeau • Aug. 6, 2026

FDA allows unique endpoint in rare disease study

Global regulators are allowing the company to use hospitalization as the primary efficacy endpoint in its registration trial for a rare neuromuscular disorder.

By Alexandra Pecci • Aug. 5, 2026

Merck is pharma’s most patent-exposed company. Now it’s reinventing itself.

Keytruda made Merck an oncology powerhouse, but as the patent cliff looms, its business development leader outlines what’s next. 

By Meagan Parrish • Aug. 5, 2026

Three potential takeover targets in psychedelics

Lilly’s recent deal to acquire AtaiBeckley gave the field a boost, but other biotechs still need to prove their clinical and commercial potential.

By Kelly Bilodeau • Aug. 4, 2026

Trump has another tariff plan to reshore generic drug production. Will it work?

The president’s most recent tariff proposal gives pharma more time to transition its global supply chain and reshore generic drug production.

By Kelly Bilodeau • Aug. 3, 2026

The future of oral drug delivery must be sustainable

How Evonik is shaping more sustainable oral drug delivery through data and excipient innovation.

By Lucas Cusin, Global Technical Marketing Manager, Oral Drug Delivery Solutions, Evonik & Thilo Krapfl, Head of Product Line Oral Drug Delivery Solutions, Evonik • Aug. 3, 2026

Specialty pharma has an infrastructure problem, and IT can’t solve it alone

Technology to enable the specialty patient journey is becoming IT's problem, but the fix isn't becoming the expert.

By Danny Sigurdson, Founder and CEO, Courier Health • Aug. 3, 2026

Why pharma’s record-setting M&A streak is so unique

Early-stage candidates, mid-sized companies and of course, Chinese assets, are dominating the dealmaking picture this year.

By Kelly Bilodeau • July 31, 2026

Genetic clues for cell therapy toxicities; Summit’s high-stakes FDA decision

Researchers have pinpointed genes linked to dangerous CAR-T cell therapy side effects, and a predictions market weighs in on Summit’s closely-watched cancer drug.

By PharmaVoice Staff • July 31, 2026

How Telix landed a $2.1 billion radiopharma deal with Regeneron

Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement. 

By Alexandra Pecci • July 30, 2026

Kalshi is expanding online betting in drug R&D — unless detractors can stop it

Kalshi sees drug development predictions as a way to improve R&D transparency. Critics say they could create financial incentives around research and undermine public trust.

By Susanna Vogel • July 28, 2026

Brand-name drug denials are surging, especially for weight-loss

Nearly one-third of prescriptions included in a new study were rejected the first time a patient attempted to fill them.

By Alexandra Pecci • July 28, 2026

The FDA was all in on AI. Will that change?

High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.

By Kelly Bilodeau • July 24, 2026

Lilly’s leap into psychedelics; peptides in the spotlight

Eli Lilly is extending its push in neuroscience while the FDA wrestles with controversial peptide drugs. 

By PharmaVoice Staff • July 24, 2026

Biopharma challenges leaders want to tackle

Boosting public trust, delivering genuine breakthroughs and getting trials off the ground remain top-of-mind issues in the industry.

By Meagan Parrish • July 23, 2026

Why the FDA’s top spot could sit empty for months

Multiple factors could get in the way of confirming a new commissioner before the midterm elections, experts said, leaving the agency’s long-term initiatives in limbo.

By Susanna Vogel • July 22, 2026

Beyond weight loss: Lilly aims for leadership in brain science

Lilly’s neuroscience chief discusses the large pharma’s aims in brain science, and how diagnostics and dosing are driving its next advancements in Alzheimer’s.

By Kelly Bilodeau • July 21, 2026